...of stapled peptides derived from the antimicrobial peptide (AMP) magainin II. Computational design of stapled magainin...
...Aug. 19, 2019 doi:10.1038/s41587-019-0222-z CONTACT: Loren D. Walensky, Dana-Farber Cancer Institute, Boston, Mass. e-mail: loren_walensky@dfci.harvard.edu Sandi Wong Magainin Dana-Farber...

...First-generation attempts to develop these peptides as therapeutics, including the magainin class of molecules from Magainin...
...added that many of the topical antimicrobial peptides in the clinic are built on the magainin...
...Haifa Bay, Israel Tuskegee University, Tuskegee, Ala. U.S. Department of Defense, Washington, D.C. Erin McCallister, Senior Editor RP182 Magainin Riptide...

...small molecule inhibitor of protein tyrosine phosphatase 1B ( PTP-1B ; PTPN1 ), from now-defunct Genaera Corp....

...SUNP), Jacksonville, Fla. Business: Autoimmune/Inflammation, Cancer, Infectious diseases Appointed: Jay Moorin, president and CEO of Magainin...

...the data support MSI-1436 as a candidate for Phase I trials to treat HIV infection. Magainin...

...the milestone and royalty rights from now-defunct Genaera Corp. (see BioCentury, May 31, 2010). In 2001, Genaera...

...IL-9. Last year, Ligand acquired the milestone and royalty rights from now-defunct Genaera Corp. In 2001, Genaera...

...research and translational science at the Georgetown University Medical Center , identified squalamine in 1993. Magainin...
...positioned it as an angiogenesis inhibitor for cancer. In 2001, Magainin changed its name to Genaera Corp....
...unlikely to improve vision with the speed or frequency necessary to compete with marketed treatments. Genaera...

...of ocular toxicity or changes in intraocular pressure. In 2009, Ohr acquired Evizon squalamine from Genaera Corp....
...to reformulate the compound to develop it for the indication (see BioCentury, Dec. 7, 2009). Genaera's...

...subcutaneous MEDI-528. Last May, Ligand acquired the milestone and royalty rights to MEDI-528 from Genaera Corp. Genaera...
...to develop mAbs against IL-9 (see BioCentury, May 31, 2010). Genaera's assets were transferred to Genaera...